FDAnews
www.fdanews.com/articles/131058-shionogi-8217-s-adhd-treatment-kapvay-gains-fda-approval

Shionogi’s ADHD Treatment Kapvay Gains FDA Approval

October 13, 2010
Japanese drugmaker Shionogi has received approval from the FDA for its attention-deficit drug Kapvay. The drug, an oral, nonstimulant, twice-daily therapy, is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents age 6 to 17, Shionogi said. Kapvay (clonidine HCl extended-release) is the first FDA-approved ADHD treatment indicated for use as an add-on therapy to stimulant medication, the company added. The drug also can be taken as a monotherapy.
Washington Drug Letter